Lynk Pharmaceuticals – Patient Worthy

Lynk Pharmaceuticals Achieves Regulatory Milestone: Zemprocitinib Advances in China for Atopic Dermatitis Treatment

Post author:Bree Clare
Post published:April 23, 2026
Post category:Atopic dermatitis

Lynk Pharmaceuticals announced a significant development in its pipeline with the China National Medical Products Administration (NMPA) formally accepting the New Drug Application (NDA) for zemprocitinib capsules to treat moderate-to-severe…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More